C4 Therapeutics, Inc.
Business
C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies using its proprietary TORPEDO platform to design small-molecule protein degraders. The company's pipeline includes cemsidomide, an IKZF1/3 degrader in Phase 2 development for multiple myeloma, and CFT8919, an EGFR L858R degrader in Phase 1 for non-small-cell lung cancer, alongside preclinical programs in inflammation, neuroinflammation, and neurodegeneration. C4 operates through strategic collaborations with Merck KGaA, Roche, Biogen, and Betta Pharma, retaining commercialization rights in most territories outside of Greater China for CFT8919.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | — | — | — | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 75 | 55 | 127 | 30 | 76 | |
| Marketable securities, current | 174 | 189 | 127 | 246 | 233 | |
| Accounts receivable | 2 | 3 | 12 | 1 | 6 | |
| Prepaid expenses and other current assets | 7 | 10 | 6 | 10 | 11 | |
| Total current assets | 258 | 258 | 271 | 288 | 326 | |
| Marketable securities, non-current | 49 | 22 | 28 | 61 | 142 | |
| Property and equipment, net | 5 | 6 | 7 | 7 | 3 | |
| Right-of-use asset | 41 | 58 | 64 | 70 | 32 | |
| Restricted cash | 3 | 3 | 3 | 3 | 3 | |
| Other assets | 4 | 3 | 3 | 2 | 544,000 | |
| Total assets | 359 | 350 | 376 | 431 | 507 | |
| Accounts payable | 858,000 | 1 | 1 | 1 | 5 | |
| Accrued expenses and other current liabilities | 13 | 19 | 21 | 20 | 14 | |
| Deferred revenue, current | 12 | 19 | 15 | 17 | 32 | |
| Operating lease liability, current | 6 | 6 | 5 | 5 | 1 | |
| Total current liabilities | 33 | 45 | 43 | 45 | 51 | |
| Deferred revenue, net of current | 16 | 28 | 22 | 17 | 24 | |
| Operating lease liability, net of current | 54 | 60 | 66 | 71 | 31 | |
| Total liabilities | 102 | 134 | 130 | 142 | 117 | |
| Commitments and contingencies (See Note 6 and Note 9) | — | — | — | — | — | |
| Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized, and no shares issued or outstanding as of December 31, 2025 and 2024, respectively | 0 | 0 | 0 | 0 | 0 | |
| Common stock, par value of $0.0001 per share; 300,000,000 and 150,000,000 shares authorized as of December 31, 2025 and December 31, 2024, and 96,914,418 and 70,625,899 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 9,000 | 7,000 | 6,000 | 5,000 | 5,000 | |
| Additional paid-in capital | 995 | 850 | 775 | 689 | 658 | |
| Accumulated other comprehensive income | 50,000 | 53,000 | −127,000 | −4 | −775,000 | |
| Accumulated deficit | −739 | −634 | −528 | −396 | −268 | |
| Total stockholders equity | 257 | 216 | 246 | 289 | 390 | |
| Total liabilities and stockholders equity | 359 | 350 | 376 | 431 | 507 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 19 | 30 | 27 | 30 | 22 | |
| Depreciation and amortization | 2 | 2 | 2 | 2 | 1 | |
| Reduction in carrying amount of right-of-use asset | 6 | 6 | 6 | 6 | 1 | |
| Accretion of premium on marketable securities | −3 | −5 | −4 | 714,000 | 2 | |
| Other | 99,000 | 6,000 | 77,000 | 0 | — | |
| Accounts receivable | 701,000 | 9 | −10 | 4 | −1 | |
| Prepaid expenses and other current and long-term assets | 1 | −4 | 3 | 388,000 | −6 | |
| Accounts payable | −468,000 | −119,000 | 273,000 | −3 | −1 | |
| Accrued expenses and other current liabilities | −6 | −1 | 1 | 5 | 4 | |
| Operating lease liability | −6 | −5 | −5 | −507,000 | −888,000 | |
| Deferred revenue | −19 | 10 | 4 | −23 | −25 | |
| Net cash used in operating activities | −99 | −65 | −107 | −106 | −87 | |
| Proceeds from maturities of marketable securities | 219 | 233 | 290 | 283 | 350 | |
| Purchase of marketable securities | −227 | −284 | −130 | −220 | −538 | |
| Purchases of property and equipment | −607,000 | −180,000 | −2 | −5 | −1 | |
| Net cash used in investing activities | −9 | −51 | 158 | 58 | −189 | |
| Proceeds from exercises of stock options | 107,000 | 778,000 | 58,000 | 777,000 | 2 | |
| Payments for repurchase of common stock for tax withholding | −193,000 | −194,000 | −110,000 | 0 | — | |
| Other | 274,000 | 382,000 | 368,000 | 370,000 | −109,000 | |
| Net cash provided by financing activities | 126 | 45 | 45 | 1 | 171 | |
| Net change in cash, cash equivalents and restricted cash | 19 | −71 | 97 | −46 | −105 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is C4 Therapeutics, Inc.'s CIK number?
C4 Therapeutics, Inc.'s SEC CIK number is 0001662579 (1662579). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find C4 Therapeutics, Inc.'s SEC filings?
All of C4 Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did C4 Therapeutics, Inc. last report earnings?
C4 Therapeutics, Inc. (CCCC) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-033861). This is C4 Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is C4 Therapeutics, Inc.'s most recent earnings 8-K?
C4 Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001628280-26-033861. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View C4 Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →